Serenity: POET Photonics Interconnect Demand Outlook Positive, Laser Supply Constraints Expected to Persist Until 2029
BlockBeats News, June 29th, Serenity reported that Poet Technologies management indicated that currently the top three global laser suppliers collectively control approximately 68% of the market share, and their capacity for the next two years has already been fully booked. This implies that after LITE's CEO previously predicted tight laser supply would continue until 2028, POET's statement further suggests that the supply shortage may persist until 2029, and the optoelectronics industry still faces a key component bottleneck.
POET also disclosed that the company is engaging with a new customer on a high-power External Light Source (ELS) project based on its Interposer platform, with mass production ramp-up expected to start in the second half of this year. Furthermore, the company expects its commercial collaboration with Lumilens to contribute over $500 million in revenue over the next five years, and market rumors suggest that Lumilens' first customer is one of the top three global hyperscale cloud service providers.
In terms of capacity planning, POET stated that the current annual production capacity of the optical engine is about 1 million units, and it is expected that by the end of 2027, market demand will increase to approximately 1 million units per month, equivalent to requiring about a tenfold capacity expansion. Serenity believes that if the company can achieve the aforementioned capacity and commercialization goals, its development prospects will be very positive. However, as the specific hyperscale customer names have not been disclosed yet, compared to some competitors who have publicly announced customer resources, its growth outlook still needs further validation.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cambium Networks UK unit enters administration in England, Wales
Market Chatter: OpenAI's Altman Says No IPO This Year
Moleculin Biotech says AACR pancreatic cancer conference features new Annamycin trial data
Bowman Consulting Ends Go-Shop Period With no Competing Offers
